News

Fierce Pharma1d
With Opella proceeds burning a hole in its pocket, Sanofi snaps up Blueprint for $9.1B
With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...
Sanofi finds M&A fix for its multiple itches
The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...
Fierce Biotech1d
Sanofi pays $15M for another STAT6 degrader from fruitful Nurix collab
Sanofi paid $55 million to partner with the biotech in 2019 and handed over a further $22 million to expand the collaboration ...
Fierce Pharma11h
ASCO: Sanofi shows investigational Sarclisa SC, delivered by on-body device, measures up to its IV formulation
Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...
Sanofi to buy US biopharma group Blueprint for over $9 billion
France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost its position in ...
Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover
French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...
Sanofi: Finding Value In The Wake Of Itepekimab's Disappointment
Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...
Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials
Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...